Table 3. Treatment of cells with... | American Society of Hematology

Table 3.

Treatment of cells with chemotherapy followed by treatment with CEP-701

	Cytarabine					Daunorubicin					Etoposide
	IC₅₀, nM	CI, 10 nM	CI, 20 nM	IC₅₀, nM	CI, 10 nM	CI, 20 nM	IC₅₀, nM	CI, 10 nM	CI, 20 nM	IC₅₀, nM	CI, 10 nM	CI, 20 nM
MV4-11	302	0.369	0.503	98	0.823	0.506	1 801	0.362	0.230	17	0.373	0.247
BaF3/ITD	1583	0.804	0.677	170	0.574	0.564	13 310	0.515	0.507	15	0.657	0.634
AML/ITD	ND	ND	ND	117	0.882	0.921	21 000	0.729	0.688	15	0.839	0.909
HL60	1325	1.068	1.074	366	0.928	1.021	14 470	0.927	0.946	119	1.120	0.937

	Cytarabine					Daunorubicin					Etoposide
	IC₅₀, nM	CI, 10 nM	CI, 20 nM	IC₅₀, nM	CI, 10 nM	CI, 20 nM	IC₅₀, nM	CI, 10 nM	CI, 20 nM	IC₅₀, nM	CI, 10 nM	CI, 20 nM
MV4-11	302	0.369	0.503	98	0.823	0.506	1 801	0.362	0.230	17	0.373	0.247
BaF3/ITD	1583	0.804	0.677	170	0.574	0.564	13 310	0.515	0.507	15	0.657	0.634
AML/ITD	ND	ND	ND	117	0.882	0.921	21 000	0.729	0.688	15	0.839	0.909
HL60	1325	1.068	1.074	366	0.928	1.021	14 470	0.927	0.946	119	1.120	0.937

Table shows IC₅₀ and CI values for the combination of 10 nM or 20 nM CEP-701 and chemotherapeutic agents at doses corresponding to the approximate IC₅₀. In this posttreatment scenario, cells were exposed to chemotherapy for 24 hours (cytarabine only), or 1 hour (daunorubicin, etoposide, or mitoxantrone), washed, and then transferred into medium containing CEP-701. MTT assays were then performed 48 hours later. Each CI value was obtained by conducting dose-response experiments for CEP-701 and the indicated chemotherapy individually and in combination over a range of doses for both drugs. ND indicates not determined.

View Large

This Feature Is Available To Subscribers Only